%0 Journal Article %A YASUYOSHI OKAMURA %A TOMOAKI TERAKAWA %A MARIKO SAKAMOTO %A YUKARI BANDO %A KOTARO SUZUKI %A TAKUTO HARA %A JUNYA FURUKAWA %A KENICHI HARADA %A NOBUYUKI HINATA %A YUZO NAKANO %A MASATO FUJISAWA %T Presurgical Pazopanib Improves Surgical Outcomes for Renal Cell Carcinoma With High-level IVC Tumor Thrombosis %D 2019 %R 10.21873/invivo.11698 %J In Vivo %P 2013-2019 %V 33 %N 6 %X Background/ Aim: We evaluated surgical outcomes following nephrectomy and thrombectomy with and without presurgical treatment with pazopanib in patients with advanced renal cell carcinoma with inferior vena caval tumor thrombosis. Materials and Methods: We compared surgical outcomes between patients undergoing presurgical treatment with pazopanib vs. surgery-alone in 19 patients who underwent surgery for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis at the Kobe University Hospital. Results: Comparing the presurgical group with the surgery-alone group, respectively, the average operative time was 497 min vs. 627 min (p=0.08); average blood loss was 1,928 ml vs. 7,393 ml (p<0.05); average postoperative hospitalization duration was 15.3 days vs. 21.6 days (p=0.05); and the perioperative complication rate was lower (presurgical: 33% vs. surgery-alone: 50%). Conclusion: Presurgical treatment with pazopanib decreased surgical difficulty and improved surgical outcomes for advanced renal cell carcinoma with high-level inferior vena caval tumor thrombosis. %U https://iv.iiarjournals.org/content/invivo/33/6/2013.full.pdf